OncoSec Announces First Patient Dosed in Phase 2 Trial of TAVO™ Plus OPDIVO® as Neoadjuvant Therapy for Melanoma
OncoSec Announces First Patient Dosed in Phase 2 Trial of TAVO™ Plus OPDIVO® as Neoadjuvant Therapy for Melanoma News provided by Share this article Share this article PENNINGTON, N.J. and SAN DIEGO, Jan. 8, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced the first patient was dosed in OMS-104, an investigator-initiated Phase 2 trial evaluating TAVO™ (tavokinogene telseplasmid), the Company's intratumoral DNA plasmid-based interleukin-12 (IL-12) therapy administered using its gene delivery platform (gene electrotransfer), in co...
Source: prnewswire.com